Spitler L E
Department of Medicine, University of California Medical Center, San Francisco.
J Clin Oncol. 1991 May;9(5):736-40. doi: 10.1200/JCO.1991.9.5.736.
We conducted a long-term follow-up (median, 10.5 years) of patients included in a randomized trial of levamisole versus placebo as surgical adjuvant therapy in 203 patients with malignant melanoma. Of the patients randomized, 104 received levamisole, and 99 received placebo. The results show that there is no difference between the treatment and control groups with regard to any of the three end points analyzed. These included disease-free interval, time to appearance of visceral metastasis, and survival. Moreover, there was no significant difference between the treatment and control groups after adjusting for age, sex, or stage of disease.
我们对203例恶性黑色素瘤患者进行了一项长期随访（中位随访时间为10.5年），这些患者参与了一项左旋咪唑与安慰剂作为手术辅助治疗的随机试验。在随机分组的患者中，104例接受了左旋咪唑治疗，99例接受了安慰剂治疗。结果显示，在分析的三个终点方面，治疗组和对照组之间没有差异。这三个终点包括无病间期、内脏转移出现时间和生存率。此外，在对年龄、性别或疾病分期进行调整后，治疗组和对照组之间也没有显著差异。
